ALISON BERLENBACH: Open Payments
NPI 1063187730 · WASHINGTON, DC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,514 in 40 payments from 10 companies in 2025. Trend: 2023 $0 · 2024 $1,299 · 2025 $1,514
Food & beverage: $1,437Education: $77
| Company | Payments | Amount |
|---|---|---|
| Madrigal Pharmaceuticals | 12 | $454 |
| ABBVIE INC. | 12 | $369 |
| Aimmune Therapeutics, Inc. | 1 | $124 |
| PFIZER INC. | 2 | $122 |
| Intercept Pharmaceuticals, Inc. | 1 | $111 |
| QOL Medical, LLC | 4 | $107 |
| Janssen Biotech, Inc. | 2 | $100 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $79 |
| GENZYME CORPORATION | 1 | $29 |
| Braintree Laboratories, Inc. | 1 | $17 |
Products named: REZDIFFRA, LINZESS, RINVOQ, ZENPEP, VELSIPITY, OCALIVA, Sucraid, TREMFYA.
Industry payments across DC — which companies pay providers there.
